Edition:
India

Resverlogix Corp (RVX.TO)

RVX.TO on Toronto Stock Exchange

3.03CAD
16 Nov 2018
Change (% chg)

$-0.10 (-3.19%)
Prev Close
$3.13
Open
$3.12
Day's High
$3.13
Day's Low
$3.02
Volume
27,368
Avg. Vol
88,112
52-wk High
$4.31
52-wk Low
$1.11

Summary

Name Age Since Current Position

Donald McCaffrey

2016 Chairman of the Board, President, Chief Executive Officer, Secretary

A. Brad Cann

2009 Chief Financial Officer

Jan Johansson

2004 Senior Vice President - Medical Affairs

Kenneth Lebioda

2006 Senior Vice President - Business & Corporate Development

Michael Sweeney

2014 Senior Vice President - Clinical Development

Norman Wong

Chief Scientific Officer

Eldon Smith

75 2016 Lead Director

Norma Biln

2016 Director

Shawn Lu

2016 Director

Kelly McNeill

2012 Independent Director

Kenneth Zuerblis

59 2010 Independent Director

Biographies

Name Description

Donald McCaffrey

Mr. Donald J. McCaffrey is Chairman of the Board, President, Chief Executive Officer, Secretary of Resverlogix Corp. He has almost 30 years of experience in drug discovery and development, and international conference and tradeshow management across multiple industries, including biotechnology.

A. Brad Cann

Mr. A. Brad Cann, serves as Chief Financial Officer of Resverlogix Corp. Prior to joining Resverlogix, Brad was Executive Vice President and Chief Financial Officer of Royal Host Real Estate Investment Trust, a diversified hospitality trust engaged in hotel ownership, investment, management and franchising, and Canada's second hotel REIT. Brad joined Royal Host in 2004 and held a number of senior positions and was appointed Chief Financial Officer in 2007 and Executive Vice President in 2008. Brad is a Chartered Accountant and a Chartered Business Valuator, and holds a Bachelor of Commerce from the University of Saskatchewan.

Jan Johansson

Dr. Jan O. Johansson, M.D. Ph.D. serves as Senior Vice President - Medical Affairs of Resverlogix Corp. He served as Chief Medical Officer at Nuvelo, Inc. from 2003 to 2004; Vice President, Clinical Research and Development, Lipid Sciences Inc. from 2001 to 2003; Co-Founder, Vice President, Clinical Affairs and Senior Clinical Research Fellow of Esperion Therapeutics, Inc. from 1998 to 2001. Dr. Johansson earned his MD and Ph.D. at the Karolinska Institute in Sweden and has published more than 50 peer-review medical articles.

Kenneth Lebioda

Mr. Kenneth Lebioda, BA, serves as Senior Vice President - Business & Corporate Development of Resverlogix Corp. He served as Senior Manager Market Access and Health Policy, Bristol-Myers Squibb from 1999 to 2004.

Michael Sweeney

Dr. Michael T. Sweeney, M.D., is Senior Vice President - Clinical Development of the Company. Dr. Sweeney, a cardiologist with extensive experience in pharmaceutical product development and marketing, will oversee clinical development programs for RVX-208 in cardiovascular disease (CVD), diabetes mellitus, and other indications. This will include the company's Phase 2/3 trial of RVX-208 in patients with high-risk CVD with low HDL and diabetes mellitus. Dr. Sweeney has an impressive career history, including 11 years at Pfizer Inc., holding a variety of senior-level medical and marketing positions, including Senior Director, Urology Global Medical Group Leader and Director of marketing of the Viagra(R) Worldwide Team. Prior to joining Resverlogix, Dr. Sweeney was a strategic pharmaceutical consultant for Impax Pharmaceuticals, Inc., a specialty pharmaceutical company with drug delivery and formulation technology, where he prepared a European marketing authorization application (MAA) for a product to treat neurologic disease. Prior to Impax, Dr. Sweeney was Chief Medical Officer and vice president of research and development at Depomed, Inc., where he implemented the company's strategic plan for product development activities including opportunity assessment, clinical trials and interactions with the FDA. Prior to Depomed, Dr. Sweeney was vice president of medical affairs at CV Therapeutics, Inc., where he built the medical affairs department to enable the successful launch of Ranexa(R) for patients with cardiovascular disease and chronic angina. Dr. Sweeney holds biochemistry and medical degrees from Liverpool University and an advanced medical research degree from Manchester University in the U.K. Dr. Sweeney also holds post-graduate diplomas in pharmaceutical medicine and pharmaco-epidemiology from the University of London. He also is a fellow of the Royal College of Physicians of Edinburgh.

Norman Wong

Dr. Norman Wong, BSc, MSc, M.D., FRCP(C), serves as Chief Scientific Officer of Resverlogix Corp. He served as Professor, Departments of Medicine and Biochemistry and Molecular Biology within the Faculty of Medicine the University of Calgary since 1987; Associate Dean, Research. Dr. Wong received his Bachelor of Science degree, Master of Science degree and Doctor of Medicine degree from the University of Calgary. Dr. Wong has presented at national and international medical conferences and has been the author and co-author of more than 220 articles and abstracts and has been invited to sit on more than 35 panels and committees. Dr. Wong has also acted as a consultant to several multinational pharmaceutical companies.

Eldon Smith

Dr. Eldon R. Smith, OC, M.D., FRCPC, FCAHS, FAHA, FIACS, is Lead Director of Resverlogix Corp. From 1997 until 2010, Dr. Smith has been Editor-in-Chief of the Canadian Journal of Cardiology and from 1992 to 1997, Dr. Smith was Dean of the Faculty of Medicine at the University of Calgary. Dr. Smith is a director of Canadian Natural Resources Limited, Aston Hill Financial Inc. and IntelliPharmaceuticals International Inc. In 2005, Dr. Smith was made an Officer of the Order of Canada.

Norma Biln

Mrs. Norma K. Biln Director of the company. She is the Chief Executive Officer and Co-Founder of Augurex. She has 22 years of experience in the pharmaceutical and biotech industries, commencing her career in clinical research with Pfizer Pharmaceuticals and held several positions in sales management, marketing and market access with Pfizer, Amgen and Abbott Laboratories where she won several regional and national level awards for top performance. Ms. Biln later joined Stressgen Biotechnologies as Director of Corporate Market Development and Director of Sales and Marketing for Stressgen Bioreagents. Before her role of CEO at Augurex, she worked in a senior consulting capacity with Aspreva Pharmaceuticals on Business Development, Commercial and Communications initiatives. Ms. Biln holds a Bachelor of Science and Master of Business Administration and is Chair of the Board of Directors of BioTalent Canada.

Shawn Lu

Mr. Shawn Lu is Director of the company. He is the Chief Financial Officer of HepalinkUSAInc. Mr. Lu has extensive experience in the areas of corporate finance, capital markets and investment financing spanning over 24 years. Prior positions include: Area Manager for BMO Bank ofMontreal; TD Bank Residential Mortgage Manager; TD Bank Senior Financial Advisor; Chief Financial Officer and Vice President of Corporate Finance, Shenzhen Hepalink Biopharmaceutical Co.; Vice President of Investment and Corporate Finance, Shenzhen FuTianXin Investment Co.; General Manager of Corporate Finance Department and Manager of Investment & Finance Department, China Merchant Shekou Port Co. Ltd. Mr. Lu holds the following designations: Canadian Investment Manager (CIM) and a Certified Accountant and Certified Corporate Economist inChina. He has Master of Finance Management and a Master of Corporate Economics and Business Administration.

Kelly McNeill

Mr. Kelly B. McNeill, CA, serves as Independent Director of Resverlogix Corp. He is the Executive Vice President, Finance and Administration, Chief Financial Officer and Secretary of IMRIS Inc., a provider of fully integrated image guided therapy solutions. From 2006 to 2009, Mr. McNeill was Resverlogix's Chief Financial Officer. Prior thereto, Mr. McNeill was General Manager at Haworth Ltd., a global office interiors manufacturer located in Calgary, Alberta. Mr. McNeill was previously Vice President, Finance at SMED International, a global office interiors manufacturer. Mr. McNeill is a Chartered Accountant and earned a B.Comm (Hons), and M.Acc from the University of Manitoba.

Kenneth Zuerblis

Mr. Kenneth J. Zuerblis serves as an Independent Director of Resverlogix Corp. Mr. Zuerblis received a BS in Accounting and is a Certified Public Accountant with nearly 30 years of experience, has held senior financial positions with three publicly-traded companies and has held directorships with numerous organizations. Mr. Zuerblis served as Executive Vice President and Chief Financial Officer of Savient Pharmaceuticals, Inc. from 2011 to 2012. Prior to joining Savient, Mr. Zuerblis served as Chief Financial Officer and Senior Vice President at ImClone Systems from 2008 through 2009. From 1994 through 2005, Mr. Zuerblis served as Chief Financial Officer of Enzon Pharmaceuticals Inc., and held the position of Corporate Controller from 1991 through 1994. Mr. Zuerblis began his career at KPMG, LLP in 1982 where he held management positions of increasing responsibility over a 10 year period. Mr. Zuerblis currently serves on the boards of directors (since 2012) of Stemline Therapeutics, Inc. and Zenith Epigenetics Corp. (since 2013).

Basic Compensation